231:
During Waksal's leadership of ImClone the company was engaged in early stage research projects for 15 years before filing its first drug application. Kadmon however immediately began acquiring drugs further advanced - either already marketed in the US or in the later stages of clinical development.
199:
Harlan W. Waksal, brother of Samuel Waksal, became
President and Chief Executive Officer while Samuel Waksal remained on with the title Chief of Innovation, Science and Strategy. In early 2016 Sam Waksal left Kadmon and in June the company filed paperwork for its IPO. On July 27, 2016 the company's
263:
In an acquisition atypical for a biotechnology company, an 1800-year-old
Chinese herbal formula was added to Kadmon's portfolio. PhytoCeutica's PHY906 (KD018) is a formula of four botanical products that had long been used for the treatment of gastrointestinal distress. Preclinical studies have
870:
Riesterer, Oliver; Matsumoto, Fumihiko; Wang, Li; Pickett, Jessica; Molkentine, David; Giri, Uma; Milas, Luka; Raju, Uma (2009). "A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe".
232:
It acquired the
Warrendale, PA-based company Three Rivers Pharmaceuticals and their Ribasphere and topotecan products. It also signed an agreement with Ontario, Canada-based Valeant Pharmaceuticals for their
1565:
294:
antagonist in development for cancer therapy, were acquired from
Concordia Pharmaceuticals of Fort Lauderdale, FL. It also acquired the rights from Burlington, MA-based Dyax Corp. for DX-2400, a
1540:
956:"A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer"
1555:
811:
Pietanza, M. Catherine; Gadgeel, Shirish M.; Dowlati, Afshin; Lynch, Thomas J.; Salgia, Ravi; Rowland, Kendrith M.; Wertheim, Michael S.; Price, Katharine A.; et al. (2012).
1550:
1530:
1545:
1525:
650:
1590:
264:
shown it to enhance the therapeutic activity of several anticancer agents. In 2014 KD018 was in a Phase II trial in combination with irinotecan in metastatic colon cancer.
1570:
981:
1520:
599:
382:
1133:"A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile"
1535:
705:
212:
announced it would acquire the company for $ 1.9 billion. The deal completed in
November and its stock was deregistered as it became a subsidiary of Sanofi.
320:
Entecavir tablets, a virus nucleoside analog reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection.
762:
Chmielecki, Juliann; Pietanza, M. Catherine; Aftab, Dana; Shen, Ronglai; Zhao, Zhiguo; Chen, Xi; Hutchinson, Katherine; Viale, Agnes; et al. (2012).
1033:
Boerma, Marjan; Fu, Qiang; Wang, Junru; Loose, David S; Bartolozzi, Alessandra; Ellis, James L; McGonigle, Sharon; Paradise, Elsa; et al. (2008).
679:
764:"EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib"
514:
276:
1580:
1035:"Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin"
736:
27:
1575:
1560:
624:
1261:
857:
for "A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in
Subjects With Autosomal Dominant Polycystic Kidney Disease" at
334:
192:. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed.
1214:"Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton"
457:
1374:
271:
research platform and three drug candidates in clinical development. These compounds include SLx-2119 (KD025), an inhibitor to
386:
989:
1012:"Kadmon Pharmaceuticals and Nano Terra Announce Worldwide Exclusive Licensing Agreement for Three Novel Product Candidates"
713:
585:
272:
307:
537:
559:
245:
189:
813:"Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer"
249:
1185:
Leonardi, R; Alemanni, M (2011). "The management of erectile dysfunction: Innovations and future perspectives".
295:
173:
1309:
Devy, L.; Huang, L.; Naa, L.; Yanamandra, N.; Pieters, H.; Frans, N.; Chang, E.; Tao, Q.; et al. (2009).
483:
955:
1082:
Lee, J; Zheng, Y; -von
Bornstadt, D; Wei, Y; Balcioglu, A; Daneshmand, A; Yalcin, N; et al. (2014).
185:
298:(MPP-14) targeted monoclonal antibody intended to inhibit tumor blood vessel formation and metastasis.
275:(ROCK2) with possible potential in fibrotic disease and focal cerebral ischemia. SLx-4090 (KD026) is a
1311:"Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis"
740:
314:
Capecitabine tablets, a nucleoside metabolic inhibitor for the treatment of colon and breast cancer
188:. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001
1212:
Mashiach-Farkash, E; Rak, R; Elad-Sfadia, G; Haklai, R; Carmeli, S; Kloog, Y; Wolfson, HJ (2012).
1419:
1160:
896:
858:
1332:
1287:
1243:
1194:
1152:
1113:
1064:
937:
888:
834:
793:
26:
236:
drugs ribavirin and taribavirin (now KD024). Cancer drugs XL647 and XL844 were acquired from
1322:
1233:
1225:
1144:
1103:
1095:
1054:
1046:
927:
880:
824:
783:
775:
177:
65:
1585:
431:
181:
1265:
223:
to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD.
1238:
1213:
1132:
1108:
1083:
1059:
1034:
788:
763:
280:
267:
In 2011 the company acquired rights from
Brighton, MA-based Nano Terra Inc. for their
138:
123:
capecitabine, dofetilide, entecavir, ribavirin, temozolomide, tetrabenazine, tobramycin
1514:
340:
Tobramycin, as an inhalation nebulizer solution for the treatment of cyctic fibrosis.
291:
169:
82:
37:
1164:
900:
357:
484:"Kadmon Corporation Announces the Appointment of Dr. Harlan W. Waksal as President"
327:
1327:
1310:
853:
409:
1050:
829:
812:
779:
1011:
241:
233:
220:
216:
1467:
1443:
1350:
1262:"Kadmon Acquires First-in-Class Ras Antagonist From Concordia Pharmaceuticals"
932:
915:
884:
279:(MTP) inhibitor being explored for metabolic disorders. SLx-2101 (KD027) is a
1288:"Novel MMP-14 Inhibitor to be Developed in Multi-Indication Oncology Program"
1491:
1229:
1148:
1395:
1336:
1247:
1198:
1156:
1117:
1068:
941:
892:
838:
797:
1131:
Kim, Enoch; Stewart
Campbell; Olivier Schueller; et al. (June 2011).
283:
inhibitor, a class of drug used in the treatment of erectile dysfunction.
244:(XL647, KD019) entered Phase II clinical trial for certain indications of
237:
560:"Sam Waksal's Kadmon Holdings shares open below offering price in debut"
916:"Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy"
515:"Kadmon Seeks IPO With Unusual Terms That Benefit Waksal, Debt Holders"
260:
and may increase the sensitivity of cancer cells to radiation therapy.
600:"France's Sanofi to buy U.S. biopharma firm Kadmon in $ 1.9 bln deal"
209:
205:
143:
1099:
491:
538:"Sam Waksal Exited Kadmon With $ 25M Severance Deal Ahead of IPO"
306:
As of 2019 Kadmon produces several generic drugs approved by the
257:
253:
201:
326:
Temozolomide capsules, an alkylating drug for the treatment of
680:"Tales from the Biotech Crypt: Sam Waksal Is Back in Business"
337:
inhibitor indicated for the treatment of
Huntington's disease.
196:
383:"Biotechnology Company Overview of Kadmon Corporation, LLC"
586:"Kadmon to Transfer U.S. Stock Exchange Listing to Nasdaq"
176:, PA and Brighton, MA. The company was founded in 2009 by
1566:
Companies formerly listed on the New York Stock Exchange
219:
in specific fibrotic and neurodegenerative diseases and
195:
In September 2014, amid plans to take the company to an
1084:"Selective ROCK2 Inhibition In Focal Cerebral Ischemia"
706:"Company Overview of Three Rivers Pharmaceuticals, LLC"
678:
Fitzpatrick Dimond, Ph.D., Patricia (3 November 2010).
1137:
Journal of Pharmacology and Experimental Therapeutics
153:
317:
Dofetilide capsules, a cardiac antiarrhythmic drug.
149:
137:
127:
119:
99:
89:
71:
61:
43:
33:
323:Ribavirin for the treatment of chronic hepatitis C
215:As of 2019 Kadmon had ongoing clinical trials for
737:"Valeant, Kadmon sign deals on hepatitis C drugs"
651:"ImClone Ex-Chief Embarks on New Biotech Venture"
1444:"Temozolomide capsules, prescribing information"
16:Biopharmeceutical company based in New York City
1541:Health care companies based in New York (state)
1468:"Tetrabenazine tablet, prescribing information"
1088:Annals of Clinical and Translational Neurology
686:. Genetic Engineering & Biotechnology News
1556:Pharmaceutical companies of the United States
1375:"Dofetilide capsules, drug label information"
8:
1551:Biotechnology companies of the United States
1531:Pharmaceutical companies established in 2009
432:"Former Imclone Chief Acquires Drug Company"
252:. XL844 is an inhibitor of protein kinases
19:
1546:Technology companies based in New York City
1526:Biotechnology companies established in 2009
240:. An inhibitor of several protein kinases,
1591:American subsidiaries of foreign companies
358:"Company Overview of Kadmon Holdings, LLC"
168:) is a biopharmaceutical company based in
25:
18:
1326:
1237:
1187:Archivio Italiano di Urologia, Andrologia
1107:
1058:
931:
828:
787:
914:Liu, Shwu-Huey; Cheng, Yung-Chi (2012).
673:
671:
410:"Sam Waksal, Kadmon Pharmaceuticals CEO"
1571:Companies formerly listed on the Nasdaq
1351:"Capecitabine, prescribing information"
584:Kadmon Corporation (October 13, 2020).
464:. US Securities and Exchange Commission
349:
1521:American companies established in 2009
644:
642:
208:in October 2020. On 8 September 2021,
204:under the symbol KDMN but switched to
7:
1536:2009 establishments in New York City
1492:"Tobramycin prescribing information"
1396:"Entecavir, prescribing information"
1039:Blood Coagulation & Fibrinolysis
962:. U.S. National Institutes of Health
490:. Kadmon Corporation. Archived from
649:Pollack, Andrew (31 October 2012).
14:
739:. Thomson Reuters. Archived from
335:vesicular monoamine transporter 2
286:In 2012 the rights to salirasib (
982:"Company Overview of Nano-Terra"
735:Ho, Solarina (1 November 2010).
488:Kadmon Corporation Announcements
458:"2012 Private financing $ 50MIL"
1264:. BioSpace, Inc. Archived from
988:. Bloomberg.com. Archived from
712:. Bloomberg.com. Archived from
536:Carroll, John (June 10, 2016).
385:. Bloomberg.com. Archived from
1420:"Ribashpere label information"
625:"35 Studies found for: Kadmon"
1:
1581:2021 mergers and acquisitions
1328:10.1158/0008-5472.CAN-08-3255
277:triglyceride transfer protein
172:. It also has operations in
1576:Companies based in Manhattan
1051:10.1097/MBC.0b013e32830b2891
920:Journal of Ethnopharmacology
830:10.1097/JTO.0b013e31824c943f
817:Journal of Thoracic Oncology
780:10.1097/JTO.0b013e31823c5aee
768:Journal of Thoracic Oncology
588:(Press release). Accesswire.
513:Lash, Alex (June 13, 2016).
308:Food and Drug Administration
180:, founder and former CEO of
1561:Biopharmaceutical companies
330:multiforme and astrocytoma.
296:Matrix metalloproteinase-14
200:stock began trading on the
49:; 15 years ago
1607:
281:phosphodiesterase 5 (PDE5)
246:non-small cell lung cancer
190:ImClone stock trading case
933:10.1016/j.jep.2012.01.047
885:10.1007/s10637-009-9361-2
873:Investigational New Drugs
333:Tetrabenazine tablets, a
250:polycystic kidney disease
24:
684:Insight&Intelligence
310:in the United States.
184:, now fully merged into
20:Kadmon Corporation, LLC.
1230:10.18632/oncotarget.525
1149:10.1124/jpet.110.177527
111:Anastasios G. Konidaris
986:Bloomberg Businessweek
851:Clinical trial number
710:Bloomberg Businessweek
269:Pharmacomer Technology
166:Kadmon Pharmaceuticals
627:. Clinical Trials.gov
186:Eli Lilly and Company
76:450 East 29th Street,
227:Product acquisitions
105:Harlan W. Waksal, MD
716:on January 18, 2013
494:on 13 November 2014
389:on January 19, 2013
129:Number of employees
91:Number of locations
21:
1290:. Dyax Corporation
960:ClinicalTrials.gov
859:ClinicalTrials.gov
655:The New York Times
436:The New York Times
408:Bartiromo, Maria.
162:Kadmon Corporation
114:(Interim Chairman)
78:New York, NY 10016
438:. 25 October 2010
159:
158:
1598:
1506:
1505:
1503:
1501:
1496:
1488:
1482:
1481:
1479:
1477:
1472:
1464:
1458:
1457:
1455:
1453:
1448:
1440:
1434:
1433:
1431:
1429:
1424:
1416:
1410:
1409:
1407:
1405:
1400:
1392:
1386:
1385:
1383:
1381:
1371:
1365:
1364:
1362:
1360:
1355:
1347:
1341:
1340:
1330:
1306:
1300:
1299:
1297:
1295:
1284:
1278:
1277:
1275:
1273:
1258:
1252:
1251:
1241:
1209:
1203:
1202:
1182:
1176:
1175:
1173:
1171:
1128:
1122:
1121:
1111:
1079:
1073:
1072:
1062:
1030:
1024:
1023:
1021:
1019:
1008:
1002:
1001:
999:
997:
992:on June 23, 2013
978:
972:
971:
969:
967:
952:
946:
945:
935:
911:
905:
904:
867:
861:
849:
843:
842:
832:
808:
802:
801:
791:
759:
753:
752:
750:
748:
743:on March 3, 2016
732:
726:
725:
723:
721:
702:
696:
695:
693:
691:
675:
666:
665:
663:
661:
646:
637:
636:
634:
632:
621:
615:
614:
612:
611:
596:
590:
589:
581:
575:
574:
572:
570:
556:
550:
549:
547:
545:
533:
527:
526:
524:
522:
510:
504:
503:
501:
499:
480:
474:
473:
471:
469:
454:
448:
447:
445:
443:
428:
422:
421:
419:
417:
405:
399:
398:
396:
394:
379:
373:
372:
370:
368:
354:
178:Samuel D. Waksal
115:
109:
66:Samuel D. Waksal
57:
55:
50:
29:
22:
1606:
1605:
1601:
1600:
1599:
1597:
1596:
1595:
1511:
1510:
1509:
1499:
1497:
1494:
1490:
1489:
1485:
1475:
1473:
1470:
1466:
1465:
1461:
1451:
1449:
1446:
1442:
1441:
1437:
1427:
1425:
1422:
1418:
1417:
1413:
1403:
1401:
1398:
1394:
1393:
1389:
1379:
1377:
1373:
1372:
1368:
1358:
1356:
1353:
1349:
1348:
1344:
1315:Cancer Research
1308:
1307:
1303:
1293:
1291:
1286:
1285:
1281:
1271:
1269:
1268:on 3 March 2016
1260:
1259:
1255:
1211:
1210:
1206:
1184:
1183:
1179:
1169:
1167:
1130:
1129:
1125:
1100:10.1002/acn3.19
1081:
1080:
1076:
1032:
1031:
1027:
1017:
1015:
1010:
1009:
1005:
995:
993:
980:
979:
975:
965:
963:
954:
953:
949:
913:
912:
908:
869:
868:
864:
850:
846:
810:
809:
805:
761:
760:
756:
746:
744:
734:
733:
729:
719:
717:
704:
703:
699:
689:
687:
677:
676:
669:
659:
657:
648:
647:
640:
630:
628:
623:
622:
618:
609:
607:
598:
597:
593:
583:
582:
578:
568:
566:
558:
557:
553:
543:
541:
540:. FierceBiotech
535:
534:
530:
520:
518:
512:
511:
507:
497:
495:
482:
481:
477:
467:
465:
456:
455:
451:
441:
439:
430:
429:
425:
415:
413:
407:
406:
402:
392:
390:
381:
380:
376:
366:
364:
356:
355:
351:
347:
304:
229:
182:ImClone Systems
130:
113:
112:
110:
107:
106:
102:
92:
85:
79:
77:
53:
51:
48:
17:
12:
11:
5:
1604:
1602:
1594:
1593:
1588:
1583:
1578:
1573:
1568:
1563:
1558:
1553:
1548:
1543:
1538:
1533:
1528:
1523:
1513:
1512:
1508:
1507:
1483:
1459:
1435:
1411:
1387:
1366:
1342:
1321:(4): 1517–26.
1301:
1279:
1253:
1204:
1177:
1123:
1074:
1025:
1014:. Nanowerk.com
1003:
973:
947:
906:
862:
844:
803:
754:
727:
697:
667:
638:
616:
591:
576:
551:
528:
505:
475:
449:
423:
400:
374:
348:
346:
343:
342:
341:
338:
331:
324:
321:
318:
315:
303:
300:
228:
225:
157:
156:
151:
147:
146:
141:
135:
134:
131:
128:
125:
124:
121:
117:
116:
103:
100:
97:
96:
93:
90:
87:
86:
81:
75:
73:
69:
68:
63:
59:
58:
45:
41:
40:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1603:
1592:
1589:
1587:
1584:
1582:
1579:
1577:
1574:
1572:
1569:
1567:
1564:
1562:
1559:
1557:
1554:
1552:
1549:
1547:
1544:
1542:
1539:
1537:
1534:
1532:
1529:
1527:
1524:
1522:
1519:
1518:
1516:
1493:
1487:
1484:
1469:
1463:
1460:
1445:
1439:
1436:
1421:
1415:
1412:
1397:
1391:
1388:
1376:
1370:
1367:
1352:
1346:
1343:
1338:
1334:
1329:
1324:
1320:
1316:
1312:
1305:
1302:
1289:
1283:
1280:
1267:
1263:
1257:
1254:
1249:
1245:
1240:
1235:
1231:
1227:
1224:(6): 629–39.
1223:
1219:
1215:
1208:
1205:
1200:
1196:
1192:
1188:
1181:
1178:
1166:
1162:
1158:
1154:
1150:
1146:
1143:(3): 775–85.
1142:
1138:
1134:
1127:
1124:
1119:
1115:
1110:
1105:
1101:
1097:
1093:
1089:
1085:
1078:
1075:
1070:
1066:
1061:
1056:
1052:
1048:
1045:(7): 709–18.
1044:
1040:
1036:
1029:
1026:
1013:
1007:
1004:
991:
987:
983:
977:
974:
961:
957:
951:
948:
943:
939:
934:
929:
926:(3): 614–23.
925:
921:
917:
910:
907:
902:
898:
894:
890:
886:
882:
879:(3): 514–22.
878:
874:
866:
863:
860:
856:
855:
848:
845:
840:
836:
831:
826:
823:(5): 856–65.
822:
818:
814:
807:
804:
799:
795:
790:
785:
781:
777:
774:(2): 434–42.
773:
769:
765:
758:
755:
742:
738:
731:
728:
715:
711:
707:
701:
698:
685:
681:
674:
672:
668:
656:
652:
645:
643:
639:
626:
620:
617:
605:
601:
595:
592:
587:
580:
577:
565:
561:
555:
552:
544:September 25,
539:
532:
529:
521:September 25,
516:
509:
506:
493:
489:
485:
479:
476:
463:
459:
453:
450:
437:
433:
427:
424:
411:
404:
401:
388:
384:
378:
375:
363:
362:Bloomberg L.P
359:
353:
350:
344:
339:
336:
332:
329:
325:
322:
319:
316:
313:
312:
311:
309:
301:
299:
297:
293:
289:
284:
282:
278:
274:
270:
265:
261:
259:
255:
251:
247:
243:
239:
235:
226:
224:
222:
218:
213:
211:
207:
203:
198:
193:
191:
187:
183:
179:
175:
171:
170:New York City
167:
163:
155:
152:
148:
145:
142:
140:
136:
132:
126:
122:
118:
104:
98:
94:
88:
84:
83:United States
74:
70:
67:
64:
60:
46:
42:
39:
38:Biotechnology
36:
32:
28:
23:
1498:. Retrieved
1486:
1474:. Retrieved
1462:
1450:. Retrieved
1438:
1426:. Retrieved
1414:
1402:. Retrieved
1390:
1378:. Retrieved
1369:
1357:. Retrieved
1345:
1318:
1314:
1304:
1292:. Retrieved
1282:
1270:. Retrieved
1266:the original
1256:
1221:
1217:
1207:
1190:
1186:
1180:
1168:. Retrieved
1140:
1136:
1126:
1091:
1087:
1077:
1042:
1038:
1028:
1016:. Retrieved
1006:
994:. Retrieved
990:the original
985:
976:
964:. Retrieved
959:
950:
923:
919:
909:
876:
872:
865:
852:
847:
820:
816:
806:
771:
767:
757:
745:. Retrieved
741:the original
730:
718:. Retrieved
714:the original
709:
700:
688:. Retrieved
683:
658:. Retrieved
654:
629:. Retrieved
619:
608:. Retrieved
606:. 2021-09-08
603:
594:
579:
569:25 September
567:. Retrieved
563:
554:
542:. Retrieved
531:
519:. Retrieved
508:
496:. Retrieved
492:the original
487:
478:
466:. Retrieved
461:
452:
440:. Retrieved
435:
426:
414:. Retrieved
403:
391:. Retrieved
387:the original
377:
365:. Retrieved
361:
352:
328:glioblastoma
305:
287:
285:
273:Rho kinase 2
268:
266:
262:
230:
214:
194:
165:
164:(originally
161:
160:
72:Headquarters
1193:(1): 60–2.
1094:(1): 2–14.
854:NCT01559363
604:Reuters.com
498:13 November
242:tesevatinib
234:Hepatitis C
221:tesevatinib
217:Belumosudil
1515:Categories
1294:8 December
1272:8 December
1218:Oncotarget
1170:8 December
1018:8 December
996:8 December
747:8 December
720:8 December
690:8 December
660:8 December
610:2021-09-08
468:7 December
442:7 December
416:4 December
412:. CNBC.com
393:3 December
345:References
174:Warrendale
154:kadmon.com
101:Key people
517:. Xconomy
248:. and in
1500:March 8,
1476:March 8,
1452:March 8,
1428:March 8,
1404:March 8,
1380:March 8,
1359:March 8,
1337:19208838
1248:22776759
1199:21585174
1165:10523856
1157:21406547
1118:24466563
1069:18832915
966:9 August
942:22326673
901:20865470
893:20024691
839:22722787
798:22173702
631:March 8,
564:CNBC LLC
302:Products
238:Exelixis
120:Products
34:Industry
1239:3442289
1109:3900310
1060:2713681
789:3261336
367:8 March
150:Website
62:Founder
52: (
44:Founded
1586:Sanofi
1335:
1246:
1236:
1197:
1163:
1155:
1116:
1106:
1067:
1057:
940:
899:
891:
837:
796:
786:
462:FORM D
210:Sanofi
206:NASDAQ
144:Sanofi
139:Parent
1495:(PDF)
1471:(PDF)
1447:(PDF)
1423:(PDF)
1399:(PDF)
1354:(PDF)
1161:S2CID
897:S2CID
290:), a
288:KD032
108:(CEO)
1502:2019
1478:2019
1454:2019
1430:2019
1406:2019
1382:2019
1361:2019
1333:PMID
1296:2012
1274:2012
1244:PMID
1195:PMID
1172:2012
1153:PMID
1114:PMID
1065:PMID
1020:2012
998:2012
968:2014
938:PMID
889:PMID
835:PMID
794:PMID
749:2012
722:2012
692:2012
662:2012
633:2019
571:2016
546:2016
523:2016
500:2014
470:2012
444:2012
418:2012
395:2012
369:2019
258:Chk2
256:and
254:Chk1
202:NYSE
54:2009
47:2009
1323:doi
1234:PMC
1226:doi
1145:doi
1141:337
1104:PMC
1096:doi
1055:PMC
1047:doi
928:doi
924:140
881:doi
825:doi
784:PMC
776:doi
292:Ras
197:IPO
133:101
1517::
1331:.
1319:69
1317:.
1313:.
1242:.
1232:.
1220:.
1216:.
1191:83
1189:.
1159:.
1151:.
1139:.
1135:.
1112:.
1102:.
1090:.
1086:.
1063:.
1053:.
1043:19
1041:.
1037:.
984:.
958:.
936:.
922:.
918:.
895:.
887:.
877:29
875:.
833:.
819:.
815:.
792:.
782:.
770:.
766:.
708:.
682:.
670:^
653:.
641:^
602:.
562:.
486:.
460:.
434:.
360:.
80:,
1504:.
1480:.
1456:.
1432:.
1408:.
1384:.
1363:.
1339:.
1325::
1298:.
1276:.
1250:.
1228::
1222:3
1201:.
1174:.
1147::
1120:.
1098::
1092:1
1071:.
1049::
1022:.
1000:.
970:.
944:.
930::
903:.
883::
841:.
827::
821:7
800:.
778::
772:7
751:.
724:.
694:.
664:.
635:.
613:.
573:.
548:.
525:.
502:.
472:.
446:.
420:.
397:.
371:.
95:4
56:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
